Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIX-FP in Previously Treated Chinese Subjects With Hemophilia B
NCT06399289Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of albutrepenonacog alfa in hemophilia B (HB), sponsored by CSL Limited. Started Jul 2024; status: completed.
02
Drugs
albutrepenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT06399289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399289.